Q1: 2026-05-13 Earnings Summary
EPS of $0.57 beats by $0.96
| Revenue of $9.89M beats by $5.78M
Omeros Corporation (OMER) Q1 2026 Earnings Call May 13, 2026 4:30 PM EDT
Company Participants
Gregory Demopulos – Co-Founder, Chairman, CEO & President
David Borges – VP of Finance, Chief Accounting Officer & Treasurer
J. Whitaker
Catherine Melfi – Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems
Conference Call Participants
Jennifer Williams
Stephen Brozak – WBB Securities, LLC, Research Division
Olivia Brayer – Cantor Fitzgerald & Co., Research Division
Brandon Folkes – H.C. Wainwright & Co, LLC, Research Division
Serge Belanger – Needham & Company, LLC, Research Division
Presentation
Operator
Good afternoon, and welcome to today’s earnings call for Omeros Corporation. [Operator Instructions]
Please be advised that this call is being recorded at the company’s request, and a replay will be available on the company’s website.
I’ll now turn the call over to Jennifer Williams, Investor Relations for Omeros. Please go ahead.
Jennifer Williams
Thank you, and good afternoon, everyone. Before we begin, please note that today’s discussion will include forward-looking statements. These statements reflect management’s current expectations and beliefs as of today and are subject to risks and uncertainties that could cause actual results to differ materially.
For a detailed discussion of these risks and uncertainties, please refer to the special note regarding forward-looking statements and the Risk Factors section in our quarterly report on Form 10-Q filed today with the SEC as well as our most recent annual report on Form 10-K.
Today’s call will include a discussion of certain non-GAAP financial measures. A reconciliation of these non-GAAP measures to the corresponding GAAP measures is included within Omeros’ earnings press release issued earlier today, which is available on the Investor Relations page of our website and has been furnished with the Form 8-K we filed with the SEC earlier today.
With that, I’ll turn the call over to Dr. Greg Demopulos, Chairman
